

23 April 2024

First-in-human clinical trials begin in Singapore

Highlights

- First patient treated with Heparan Sulphate 3 (HS3) and aXOpore® via a High Tibial Osteotomy (HTO) at Singapore's National University Hospital (NUH)
- Studies seek to recruit ~12 patients to establish a safety profile for aXOpore®, and to investigate the product's efficacy to enhance osteosynthesis in HTO patients
- Targeting bone morphogenetic protein-2 (BMP-2), HS3 accelerates bone regeneration in patients undergoing knee preservation surgery via HTO
- HS3 is being developed with the Institute of Molecular and Cell Biology (IMCB) under Singapore's Agency for Science, Technology, and Research (A*STAR)

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX:OSX; Osteopore or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the successful commencement of first-in-human clinical trials for knee preservation in Singapore.

On 22 April 2024, the first patient was treated for knee preservation with Heparan Sulphate 3 (HS3) and aXOpore® via a High Tibial Osteotomy (HTO) at the National University Hospital (NUH), Singapore.

The commencement of first-in-human clinical trials comes on the back of the signing of two non-binding term sheets on 14 April 2023 with Accelerate Technologies Pte Ltd (A*STAR)¹ to commercialise groundbreaking technology that accelerates bone and tissue regeneration.

¹ Refer to ASX announcement dated 14 April 2023 "Osteopore to commercialise innovative technology that accelerates bone and tissue regeneration"



The Agency for Science, Technology and Research (A*STAR) is Singapore's leading public sector R&D agency. Through open innovation, A*STAR collaborates with partners in both the public and private sectors to benefit the economy and society.

The first-in-human study aims to recruit between 10 and 12 patients with the primary goal of investigating and establishing a safety profile for the combination of HS3 and aXOpore® (**the product**). Following the surgery, the patients will participate in post-operative rehabilitation program up to the 2-year mark, with bone union assessed at 6 and 9 months. Should the in-human clinical trial prove successful, it will result in supplementary studies to investigate the product's efficacy to enhance osteosynthesis in HTO patients.

HS3 is a glycosaminoglycan sugar that Osteopore has been developing with the Institute of Molecular and Cell Biology (IMCB) and Singapore R&D powerhouse Agency for Science, Technology, and Research, A*STAR, since 2009. HS3 has the potential to expedite bone regeneration, resulting in quicker recovery times, lower complication rates, and improved patient outcomes.

Commenting on the successful commencement of first-in-human clinical trials in Singapore, Osteopore CEO, Dr Lim Yujing, said:

"Osteopore embraces an open innovation approach to converting interesting and impactful research technology.

We are delighted to see the first-in-human clinical trial commence in Singapore with the first patient treated at NUH.

We are looking forward to the outcomes of the in-human clinical trials and will keep the market updated on the latest developments, particularly at the mid-point of the study."

ENDS

This announcement dated 23 April 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr. Yujing Lim

CEO & CTO

Osteopore Limited

E: lim_yujing@osteopore.com

Isaac Stewart

Media & Investor Relations

Cannings Purple

E: istewart@canningspurple.com.au



About Osteopore Limited

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants.

The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.

Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells.

Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Some of the statements appearing in this announcement may be in the nature of forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things. Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by a number of factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control.

The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement.

This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

